Lilly enters CIA as part of $1.4 billion settlement

Share this article:

As part of its $1.415 billion settlement for off-label marketing of Zyprexa, Eli Lilly & Co. will enter a Corporate Integrity Agreement with the HHS Office of Inspector General.

The agreement requires that Lilly: send doctors letters advising them of the settlement and giving them a means of reporting questionable conduct by sales reps; list payments to doctors on its website; and that its board and senior management regularly certify that the company is in compliance and has an effective program to stay that way.

As part of its $62 million October settlement with 32 states and the District of Columbia, Lilly agreed to furnish those state's attorney generals with a list of all healthcare professionals paid more than $100 for promotional speaking and consulting in the US. Lilly had previously announced that it would report payments to physicians of over $500 as part of a transparency initiative.

Lilly's agreement with the states, binding until 2014, includes provisions governing promotional activities, dissemination of medical information, CME grants, payments to consultants and speakers, sampling and clinical research and stipulates areas and activities which are off-limits to Lilly sales and marketing teams.

Share this article:

Email Newsletters

More in News

Sales of Biogen MS pill pick up overseas

Sales of Biogen MS pill pick up overseas

Biogen Idec is seeing strong sales for blockbuster MS drug Tecfidera, especially overseas where it's beginning to catch fire this summer.

GSK second-quarter sales disappoint

GSK second-quarter sales disappoint

Executives urge analysts to focus on the company's long-term potential.

House bill would speed approval once EU OKs same product

House bill would speed approval once EU OKs ...

The Speeding Access to Already Approved Pharmaceuticals Act of 2014 would require FDA to expedite the review of pharmaceuticals that are already approved by the European Union